Journal article icon

Journal article

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

Abstract:

PURPOSE: Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer. PATIENTS AND METHODS: Oral nelfinavir (2 x 1,250 mg) was started 3 days before and continued throughout chemoradiotherapy to 50.4 Gy (boost, 59.4 Gy) in 12 patients. Two gemcitabine dose levels (DL) were tested (200 mg/m(2) and 300 mg/m(2) on days 1, 8, 22, and 29). C...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1200/jco.2007.15.2355

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume:
26
Issue:
16
Pages:
2699-2706
Publication date:
2008-06-01
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Source identifiers:
118215
Language:
English
Keywords:
Pubs id:
pubs:118215
UUID:
uuid:383e4b88-1c73-41fb-920b-c265b65f6cfb
Local pid:
pubs:118215
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP